Atrial fibrillation (AF) is the most common type of cardiac arrhythmia that is diagnosed in clinical practice, leading to increased hospitalizations, morbidity and mortality, as well as escalating healthcare costs. AF affects two to six million people in the United States and over 30 million people worldwidAe. 1 AF, due to the increased risk of stroke and heart failure, along with the need for treatment with anticoagulants, often complicates the management of other chronic diseases. 2 AF is known to increase the risk of dementia in the elderly, 3 stroke, 4 heart failure 5 as well as sudden death. 6
Sodium current (I Na ) governs the phase 0 (upstroke) of the APD and corresponds to the depolarization of the myocardium. The sodium current determines the conduction velocity and abnormalities in phase 0 contributes to the re-entry. Studies on the ion channel remodeling, and how it leads to AF are mostly conducted in animal models.
Yue et.al, first demonstrated that atrial remodeling in the tachy-paced dogs has action potential properties similar to that of humans with AF. 10 The group demonstrated the critical role played by I Ca,L in remodeling and AP morphology in these tachy-paced dogs.
I Ca,L density decreased over the duration of AF, thus shortening the APD. Ca 2+independent transient outward current (I to ) was reduced similarly, while T-type Ca 2+ current (I Ca,T ), delayed rectifier (I Ks , I Kr , I Kur ) and inward rectifier (I K1 ) potassium currents and the Ca 2+ -dependent Cl − current were not altered. 10 In a sustained AF goat model, expression of the L-type Ca 2+ channel, and of Kv1.5 was shown to be reduced, and expression of Kv4.3 and Kv4.2 was not altered. 11 I Na and gap junctions determine conduction velocity in the heart 12 and in the dog model, conduction velocity is decreased in the atria due to the reduction of I Na current density. 13 Prolonged tachypacing also caused a decrease in the amplitude of the Ca 2+ -transients, leading to decreased contractility. 14 23, 24 Later, they also demonstrated that these receptors' binding is isoform specific-myocytes have receptors only for dihydrotestosterone (DHT) and not testosterone. 25 These receptors are functional and, depending on the stimulus, can modulate gene expression and nongenomic signaling pathways. 26 Nuclear estrogen receptors (ERs) come primarily in two types: ERα and ERβ. In addition to their expression in the uterus, ERs are widely expressed in the heart. 27 ERα is mainly located on the cardiomyocyte membrane. 27 Both receptors are found abundantly in myocyte mitochondria and regulate mitochondrial function. 28 Estrogen receptors are translocated to nuclei after exposure to 17β-estradiol. 29 Estrogen also has a direct effect on the conduction properties of cardiac myocytes. Chronic estradiol treatment has shown modulatory effects on the coronary smooth muscle K + channels 30 and the cardiac calcium channels. 31 In a canine model of ventricular arrhythmias induced after ischemia/reperfusion, estrogen administration significantly reduced the arrhythmia burden. 32 These antiarrhythmic properties are due to estrogen's effect on 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Despite the well-known physiological distinctions and outcomes between men and women with cardiovascular disease, sex-specific treatment strategies are not well studied. Further research on sex hormones and their role in the heart is key to developing personalized therapies.
QT interval affected by sex hormones
The electrocardiogram (EKG) is a simple and powerful tool used for diagnosis and prognosis in a wide range of cardiovascular diseases. An EKG is a representation of the electrical activity of the heart and consists of a P wave (atrial activation and recovery),
QRS complex (ventricular activation) and T wave (ventricular recovery). The QT interval
represents ventricular activity and is calculated from the beginning of the QRS complex p=0.0007) with the higher dose of testosterone in the injections. 61 Geraldi et al. studied QT c intervals in the hypogonadic males and compared them with the age matched controls. QT c was shown to have a higher prevalence in the hypogonodal men. 62 All these results demonstrate that both endogenous and exogenous testosterone show similar effects on shortening QT c interval.
The effect of endogenous estrogens on the QT c interval is conflicting. QT c in mice with endogenous estrogen is found to have prolonged QT c than in ovariectomized mice with no endogenous estrogen. QT c in ovariectomized mice with estradiol injections tend to restore to that of the normal mice. 63 This is in contrast to what has been observed in humans. A study in premenopausal women before and after bilateral oophorectomy showed significant decrease in the estradiol post-surgery but there was no significant change in the QT c interval. 64 Another study by Saba et al. showed that the QT c does not vary between premenopausal women (405±21 msec) and postmenopausal women even though the estrogen levels were significantly lower in the postmenopausal women (419±30 msec). 65 Progesterone, like testosterone, shortens the APD and QT c interval in women. 63 During the menstrual cycle, progesterone levels have the dominant effect on ventricular repolarization. Progesterone levels are higher in the luteal phase, during which the QT c interval is shorter in women. 41 This is also evident from studies done on women treated with menopause hormone therapy. Women placed on estrogen alone therapy have QT c prolongation compared to women on estrogen plus progesterone therapy. In the latter case, estrogen and progesterone tend to have a counterbalancing effect on the QT c interval. 50 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
LQT in women
It is well known that the QT interval is longer in women and that there is a female predominance among patients with symptomatic LQT syndrome. 66 The effect of testosterone in men may explain the lower incidence of related cardiac events in men compared to women. Furthermore, during pregnancy, hormonal changes can cause subsequent variations in QT interval. It has been previously shown that there is prolongation of the QTc in pregnant women. 67 In this study, EKGs were recorded in healthy pregnant women (36-40 weeks of gestation) and in healthy non-pregnant women. In addition, women with established LQTs have a higher risk of developing TdP in the first nine months after the pregnancy 68 and after which the risk level returns to baseline as in before the pregnancy. 69 This higher risk of arrhythmias immediately after pregnancy can be partially explained by changes in heart rate. After delivery, heart rate returns to baseline and this protection is lost, resulting in prolonged QT intervals and thus increasing the risk of having arrhythmias. 70 In addition, the associated increase in stress and lack of sleep due to child care could increase the incidence of cardiac events postpartum. β-blocker use during pregnancy and postpartum was independently associated with the decrease in cardiac events.
Pregnancy and arrhythmias
During pregnancy, incidence of supraventricular tachyarrhythmias (SVT) is increased. In a study on 60 consecutive women with SVT, it is shown that the risk of exacerbation and new onset of SVT is increased during pregnancy. 71 The risk level however was not affected by the stage of pregnancy. The exact cause of increased 
Sex-based differences in presentation, treatment and outcomes in women with

AF
Sex differences studies in the arrhythmias have relatively received less attention compared to coronary heart disease. 72 Large registry studies including Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation (RECORD AF) 73 and Eurobservational Research Programme-Atrial Fibrillation General Registry Pilot Phase, 74 focused on the AF symptoms, but there was no detailed analysis on sex differences in symptoms and quality of life. As discussed previously, women have lower incidence of AF, but the number of patients with AF above age 75 years is about same due to the fact that women outnumber men in the group with the highest percentage of AF. 75, 76 In the few studies available, it is reported that women present with higher heart rates during AF than men. 77 Women also have higher incidence of paroxysmal AF after successful cardioversion, which is attributed mainly to the greater number of reported AF episodes. 78 A study that analyzed Canadian Registry of Atrial Fibrillation (CARAF) Symptomatic females with AF more often received rate control than rhythm control while asymptomatic females received mostly rate control management. 83 Initial management of AF did not differ in men and women with AF. Digoxin is the first prescription at the baseline visit followed by antiarrhythmic drugs such as amiodarone, propafenone and sotalol. Women are less likely to undergo catheter ablation for AF.
Though permanent AF is less common in women, there is a higher rate of AV nodal ablation, which is usually a last resort for drug refractory and symptomatic AF. 84 There is also the notion of depression associated with increased AF symptoms. However, the effects of depression on the presentation of and quality of life in men and women is not 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 AF management during pregnancy is a concern for the wellbeing of both mother and fetus. The onset of episodes during pregnancy can be either primary or a recurrence of previously diagnosed AF. Most of the primary episodes are benign and thus appropriate advice and reassurance is helpful. In the episodes that are highly symptomatic and occur as a recurrence of previous AF, judicious use of antiarrhythmic therapy is required. It is a delicate balance to consider both the benefits of arrhythmia treatment and the maternal and fetal side effects of antiarrhythmic drugs. The first trimester, during which fetal organogenesis occur, possess a major risk to use any antiarrhythmic drug. If AF is associated with valvular disease such as severe mitral stenosis, it is advantageous to consider terminating AF using antiarrhythmic drugs to avoid the need for anticoagulation, because pregnancy in particular is a pro-thrombotic condition. Sotalol, atenolol, flecainide or procainamide are the preferred drugs in such cases. These drugs should be administered in the lowest effective dose and constant monitoring of mother and fetus during the treatment is recommended. Electrical cardioversion is usually safe in pregnancy irrespective of the trimester. However, it has been reported that there is remote possibility of initiating fetal arrhythmias which require emergency caesarean section. 87 There are also reported incidents where electrical 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Women, compared to men, have increased risks of deleterious arrhythmias with usage of antiarrhythmics, since they have longer QT intervals and it is known that longer QT intervals increase the risk of torsades de pointes. In a study of D,L sotalol women had 4.1% incidence of torsades compared to 1% for men. This gender specific increase was seen also in the SWORD trial and the DIAMOND-CHF trial, which evaluated usage of dofetilide. It has also been noted that women have a higher incidence of sick sinus syndrome due to antiarrhythmics such as flecainide, sotalol, and amiodarone, thus leading to increase implantation of pacemakers. 83
Invasive catheter ablation as treatment for AF
Restoration and maintenance of sinus rhythm after ablation has been known to improve quality of life, symptoms, exercise tolerance and left ventricular function.
Catheter ablation for AF may be a curative therapy for patients who are refractory to pharmacological therapy. The success of catheter ablation can be variable from 60- 85%, and highly dependent on duration of AF and structural abnormalities such as burden of atrial fibrosis and left atrial size. Paroxysmal AF is known to be more amenable to successful catheter ablation then permanent AF. Women tend to have longstanding AF, larger left atrial size and a history of not responding well to antiarrhythmics, conferring poorer outcomes. 93, 95 Women are also referred 3 times less often then men for AF ablation which may be reflective of sex bias in referral patterns, even though women with AF report poorer quality of life and have a higher risk of stroke and increased mortality. AF ablation in women may also be more technically challenging as women often had a higher incidence of nonpulmonary vein sources such as from the superior vena cava compared to men. Women also suffer from higher procedural complications. Incidence of cardiac tamponade, femoral vascular complications such as hematomas, and pseudoaneurysms are higher in women compared to men. In addition, women are often underrepresented in clinical trials of invasive procedures such as catheter ablation. Women who are enrolled in single center or multicenter trials have usually been less than 30%. 91, 96, 97 A novel transgenic mouse model used to study gender differences in AF 101 . AF is defined in these studies by a duration of at least 1 sec and most previously reported mouse models demonstrated these relatively short episodes of AF 101 A new therapeutic approach for AF was identified by pharmacologically targeting the downstream effects of enhanced Na + entry, using a relatively specific inhibitor of the Na + -Ca 2+ exchanger (NCX). 98 This model can be used for future further understanding of the gender specific differences in male and female mice with AF, and how those differences may reflect gender specific cardiac remodeling, structure and electrophysiology in men and women with AF.
Conclusion
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